Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: j_fir2 who wrote (2302)	4/14/1999 11:09:00 AM
From: BDR	Read Replies (1) of 10280

<<SEPR is preparing to go into Phase II trials on the ICE oxybutynin, and the market model that has enticed so many newcomers depends upon riding the coattails of blockbusters... >> I don't know the sales figures for Ditropan but I wouldn't call it a blockbuster. It is no Prozac, that is for sure. Incontinence is a major problem but it is a symptom that has a variety of causes, only some of which are amenable to pharmacologic correction. Anyone looking at the number of people with incontinence in this country and envisioning every one of them taking Sepracor's S-oxybutynin in five years will be sorely disappointed by the actual sales, even if S-oxy turns out to be the best incontinence drug out there. S-oxy has only completed Phase I trials and I don't think it is on anyone's radar yet. If SEPR has sold off 10-20 points because of AZA's problems with a slow release form of the racemic mixture that S-oxy might replace, then those sellers don't have a good grasp of where SEPR may be going. I don't know why the stock has moved recently as it has but it is not due to this issue in my opinion.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next